RYGB reduces microalbuminuria and A1c better than empagliflozin and liraglutide: Study

They conducted a post hoc analysis of the MOMS RCT, to determine whether the combination of two potent renoprotective medications can match the reductions of albuminuria observed after RYGB.

The results of the study are as follows:

• Both interventions resulted in significant reductions in uACR, but RYGB was significantly superior.
• The percentage of patients who achieved remission of albuminuria/DKD was 59.3% in the Combo and 81.8% in the RYGB group.
• RYGB was superior to the Combo for reductions in HbA1c and LDL cholesterol but not systolic blood pressure.
• The American Diabetes Association (ADA) triple end point was achieved in 25.9% in the Combo group and 44.2% in the RYGB group.

Thus, the researchers concluded that individuals who received RYGB had a greater reduction in microalbuminuria and A1c compared with those treated with empagliflozin and liraglutide.

Reference:

Renoprotective Effects of the Combination of Empagliflozin and Liraglutide Compared With Roux-en-Y Gastric Bypass in Early-Stage Diabetic Kidney Disease: A Post Hoc Analysis of the Microvascular Outcomes after Metabolic Surgery (MOMS) Randomized Controlled Clinical Trial by Ricardo V. Cohen published in the Diabetes Care.

https://doi.org/10.2337/dc21-1192